Periostin: A Downstream Mediator of EphB4-Induced Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells

Figure 5

Osteogenic differentiation mechanism of the EphB4 pathway. (a) POSTN treatment and integrin αvβ3 blocking were applied to MSCs for 3 days, and cell lysates (20 μg each) were subjected to western blotting. Untreated MSCs were used as the control. (b, c) The levels of inactive GSK (p-GSK-3β-Ser9/GSK-3β) and β-catenin were quantified using ImageJ2x and expressed as a fold-change over that of the control. Bars represent means ± SD from 3 biological replicates; . (d) Integrin αvβ3 blocking, ephrinB2-FC treatment, and BHG712 treatment were applied for 3 days, and cell lysates (20 μg each) were extracted for western blotting. Again, untreated MSCs were used as the control. (e, f) The levels of inactive GSK (p-GSK-3β-Ser9/GSK-3β) and β-catenin were quantified using ImageJ2x and expressed as a fold-change over that of the control. Bars represent means ± SD from 3 biological replicates; .

(a)

(b)

(c)

(d)

(e)

(f)